Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions
  • USA - English


News provided by

Ford & Associates Nationwide Legal Services, A.P.C.

Mar 02, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


“Ford & Associates acknowledges the FDA's Adverse Reactions revisions to Xarelto's labeling, and are interested in talking with people who took Xarelto prior to these revisions, and may have suffered injuries as a result."

Post this

San Diego, CA (PRWEB) March 02, 2015 -- In light of the FDA's approved revisions to the safety label of anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide Legal Services notes that these cautionary revisions may be helpful for future users, but may come too late for individuals who have already allegedly suffered injuries from taking the drug. The FDA has now included the term “thrombocytopenia,” a low blood platelet disorder, under Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” has also been replaced with “hepatitis (including hepatocellular injury).” *

Lawsuits against Xarelto allege that Janssen Pharmaceuticals, Inc., the manufacturer of Xarelto, knew of the possibility of internal bleeding and other Xarelto side effects, but didn't adequately warn of such events. According to case documents, individuals who took Xarelto have allegedly experienced severe bleeding, strokes, and fatal injuries leading to death.

“We acknowledge the FDA's Adverse Reactions revisions to Xarelto's labeling, and are interested in talking with people who took Xarelto prior to these revisions, and may have suffered injuries as a result. We are committed to helping people find the best legal representation possible, and encourage them to contact us.” – Mateo Martinez, Ford & Associates Case Manager

Xarelto (rivaroxaban) was on FDA’s 2011 Innovative Drug Approval List as a new anticoagulant used to prevent the formation of blood clots in patients who suffer from deep vein thrombosis (DVT), atrial fibrillation (irregular heart rhythms), pulmonary embolism (PE), and are at high risk of stroke. Xarelto is marketed as superior and easier to use than other anticoagulants, as the drug doesn't require dietary restriction, or tests to monitor the patients’ blood plasma levels.**

Although the FDA notes that Xarelto doesn't at present have an antidote to stop severe bleeding if it should occur, Ford & Associates has learned of studies, as reported by Reuters, that an intravenous antidote, andexanet alfa, has been developed, and is being tested for accuracy to reverse the anticoagulation activity associated with Xarelto use. Current trial data indicates that the Portola Pharmaceuticals anti-clotting drug has already experienced a high success rate of reversing internal bleeding associated with Xarelto in healthy patients aged 50-75. More testing details are suspected to be released within the coming year.***

Ford & Associates also comments that there are currently 21 Xarelto lawsuits filed and pending against the manufacturers of Xarelto (Case MDL No. 2592). In December of 2014, the U.S. Judicial Panel on Multidistrict Litigation centralized all federally-filed Xarelto lawsuits to the U.S. District Court, Eastern District of Louisiana. The U.S. Judicial Panel stated there were common issues in all Xarelto cases that allowed for centralization, such as “the adequacy of Xarelto’s warning label with respect to the risk of severe bleeding and other injuries, the results of certain clinical studies, and the alleged need for blood monitoring.” (Case MDL No. 2592).

*fda.gov/Safety/MedWatch/SafetyInformation/ucm367392.htm, FDA, December 2014
** fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf, FDA, February 2011
*** reuters.com/article/2015/01/09/us-portola-pharma-study-idUSKBN0KI1DR20150109, Reuters, January 2015

About Ford & Associates Nationwide Legal Services, A.P.C.
Ford & Associates Nationwide Legal Services, A.P.C., is a San Diego based law firm that fights aggressively for the rights of those who cannot fight for themselves. Each case is treated with unparalleled dedication, compassion, and skill, and pursued to the fullest extent as allowed by law until a favorable outcome has been reached.

If you or a loved one believe that you have suffered adverse health conditions from using Xarelto, and are seeking answers to Xarelto lawsuit and/or rivaroxaban lawsuit questions, contact Ford & Associates today at 1-866-242-0905 for a free, no-obligation case review.

Ford & Associates Nationwide Legal Services, A.P.C.
3555 4th Ave
San Diego, CA 92103
866-242-0905

ATTORNEY ADVERTISING. Ford & Associates Nationwide Legal Services, APC. This is an attorney advertisement. The information in this article is only provided for general information purposes. The information presented in this article and your viewing of the information in this article does not establish an attorney-client relationship. If you need legal assistance, we encourage you to call, write or email us. By contacting us, an attorney-client relationship has not been created. A formal attorney client-client relationship is not established until you have signed a retainer agreement and your case has been accepted. Please do not send any documents, evidence or any other information relating to your case until an attorney-client relationship has been established. Prior results do not guarantee a similar outcome with respect to any future matter. Please call or email our firm for a free, no obligation case evaluation.

Contact Information:
Mateo Martinez, Case Manager
Ford & Associates Nationwide Legal Services, A.P.C.
3555 4th Ave
San Diego, CA 92103
866-242-0905
drug-lawsuits.com

Mateo Martinez, Ford & Associates Nationwide Legal Services, A.P.C., http://drug-lawsuits.com, +1 866-242-0905, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.